Compliance Certificate under SEBI Regulations 2018
Tatva Chintan Pharma Chem Limited submitted a compliance certificate under SEBI regulations for the quarter ended September 30, 2025.
Compliance filings are generally considered to have a low impact.
This is a routine compliance filing, so the sentiment is neutral.
* Compliance certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30 September 2025 received from MUFG Intime India Private Limited, Registrar and Share Transfer Agent.
What to do with a filing like this
Tatva Chintan Pharma Chem Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Tatva Chintan Pharma Chem Limited. Read the original for the full detail.